Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer
Authors:
- X WeiXWX Wei
- A SaponeASA Sapone
- O BrownOBO Brown
- S HardySHS Hardy
- P CanneyPCP Canney
- P Fernandez-SalgueroPFP Fernandez-Salguero
- Fj GonzalezFGFj Gonzalez
- J CassidyJCJ Cassidy
- HL McLeodHMHL McLeod
Open Access
- 1 February 1998
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 77 (3) , 497-500
Abstract
Individuals with a deficiency in the enzyme dihydropyrimidine dehydrogenase (DPD) may experience severe life-threatening toxicity when treated with 5-fluorouracil (5-FU). As routine measurement of enzyme activity is not practical in many clinical centres, we have investigated the use of DNA mutation analysis to identify cancer patients with low enzyme levels. We have identified two new mutations at codons 534 and 543 in the DPD cDNA of a patient with low enzyme activity and screened the DNA from 75 colorectal cancer patients for these mutations and the previously reported splice site mutation (Vreken et al, 1996; Wei et al, 1996). In all cases, DPD enzyme activity was also measured. The splice site mutation was detected in a patient (1 out of 72) with low enzyme activity whereas mutations at codons 534 (2 out of 75) and 543 (11 out of 23) were not associated with low enzyme activity. These studies highlight the need to combine DPD genotype and phenotype analysis to identify mutations that result in reduced enzyme activity.Keywords
This publication has 15 references indexed in Scilit:
- Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.Journal of Clinical Investigation, 1996
- Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfectaEuropean Journal of Cancer, 1996
- Population study of dihydropyrimidine dehydrogenase in cancer patients.Journal of Clinical Oncology, 1994
- cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria.Journal of Biological Chemistry, 1994
- Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy.1993
- Severe Fluorouracil Toxicity in a Patient With Dihydropyrimidine Dehydrogenase DeficiencyJNCI: Journal of the National Cancer Institute, 1993
- Severe 5-Fluorouracil Toxicity in a Patient with Decreased Dihydropyrimidine Dehydrogenase ActivityCancer Investigation, 1993
- Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients.1992
- Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity.Journal of Clinical Investigation, 1988
- CLINICAL PHARMACOKINETICS OF 5-FLUOROURACIL AND ITS METABOLITES IN PLASMA, URINE, AND BILE1987